Hangzhou Tigermed Updates 2025 Final Dividend Terms and Tax Treatment

An update from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.

Hangzhou Tigermed Consulting has announced an updated final cash dividend for the year ended 31 December 2025, declaring a payout of RMB 1.26 per 10 shares, subject to shareholder approval on 2 June 2026. The dividend for Hong Kong shareholders will be paid in Hong Kong dollars on 31 July 2026, with the exact HKD amount and exchange rate to be announced, while key dates such as the ex-dividend date, record date and book closure period remain pending.

The company has also clarified withholding tax arrangements for different categories of investors, including 10% withholding for non-resident enterprise and individual investors in its Shenzhen-listed A shares, and 20% withholding on dividends for mainland individual investors accessing its H shares via the Southbound Trading Link. These details provide greater transparency on post-tax returns for both domestic and cross-border shareholders, underscoring Tigermed’s efforts to align its distribution practices with Chinese tax regulations and Hong Kong market disclosure standards.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a Hong Kong-listed company providing clinical research and related consulting services to the pharmaceutical and life sciences industries. Its Class H shares trade on the Hong Kong Stock Exchange, while its A shares are listed on the Shenzhen Stock Exchange, giving it exposure to both mainland Chinese and international investors.

Average Trading Volume: 1,814,582

Technical Sentiment Signal: Sell

Current Market Cap: HK$49.1B

See more data about 3347 stock on TipRanks’ Stock Analysis page.